Article: Co-inhibition of BRAF and MEK signalling delays progression in BRAF-mutant metastatic melanoma

Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma